DOCSLIB.ORG

Danish Dynamite: Top 25 Supply Chain Executives 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Danish Dynamite: Top 25 Supply Chain Executives 2020 Fourth ranking of Denmark’s supply chain leaders Danish Dynamite: Top 25 Supply Chain Executives 2020 For the fourth consecutive year, Based on a thorough and exten- The award is sponsored Supply Chain Leaders Forum sive analysis of a triple-digit by Syncronic Management (SCLF) is celebrating the foste- number of very strong leaders Consulting and consists of ring of great supply chain lea- across Danish companies and a creative statuette by artist ders at Copenhagen Business organizations, SCLF and the lea- Åse Højer, and a valuable School. SCLF is a collaboration ding headhunter Korn Ferry have SCM problem analysis. between CBS, DTU, IDA Operati- evaluated and prepared a ran- ons Management and the associ- king of the Top 25 Supply Chain ation AAASCM. Executives in Denmark. By Henrik Knak, Partner in Syncronic Management Consulting SUPPLY CHAIN LEADERS FORUM The 9th Supply Chain Leaders Forum many exciting presentations and discus- and the association AAASCM, with a strong Ferry represented by senior client partner 2020 very early in the annual preparations sions. From reinventing the business mod- support from Syncronic. In addition to Katriina Lillelund Schøier, member of the during springtime concluded that the el, over circular economy tier-1 and tier-2 honoring students from both CBS and DTU global Supply Chain & Operations COE. corona-situation would force the event to collaboration to the challenge of turning for the best academic assignments that bring This year, Torsten Steenholt, Executive re-innovate itself and to go online. Hence, the green business case into real value and value to business, the conference reached its Vice President and Chief Operating Officer we transformed the event to a studio-based harvesting the benefits. peak with the unveiling of the best supply at Chr. Hansen A/S ranked #1 in Denmark. setup with guest speakers from around The main purpose of the conference was chain leader in Denmark 2020. The award the world and with a few guest physically to bridge research and business, education was presented by partner in Syncronic Hen- Ranking Denmark’s Top 25 visiting the SCLF studio located at CBS and practice across commercial and techni- rik Knak grounded in a thorough analysis To produce this ranking of the Top 25 in Copenhagen. Supported by technicians, cal domains. This conference is a unique ex- that includes a broad and comprehensive Supply Chain Executives in Denmark, professional video and sound equipment, ample of how business and technical univer- assessment of many criteria. The data we initiated with a long list of triple-digit and members from the involved organ- sities and private companies can collaborate collection, analysis and the final selection number of senior leaders in bigger isations: CBS, DTU, IDA Operations across institutions. The event is organized were carried out by the SCLF board in close companies Management and AAASCM. This year, the as a collaboration between CBS – Copenha- collaboration with the executive search event attracted over 250 registered partic- gen Business School, DTU – the Technical company Korn ipants. University of Denmark, IDA Operations The conference theme ‘Green Supply Management, Chain Management – from plan to Track record & reputation action’ offered 4 Lighthouse Recommendations from leading Job 3 Danish CEOs complexity Organisational and academic Input from Korn Ferry Financial 2 roles global Supply Chain CoE performance SCOR functions covered University lectures Local market intelligence 1 Geographical footprint Conference appearances and insight from Korn Ferry Revenue Supply chain complexity Articles, interviews Peer review from EBIT Supply chain maturity and SCM statements SCM professors and consultants Return on Capital Employed (ROCE) Growth in Revenue Growth in EBIT Growth in ROCE RANKING CRITERIA Top 25 Ranking Supply Chain Executives 2020 2 SUPPLY CHAIN LEADERS FORUM situated in Denmark. We then took the for each of the Supply Chain Executive. models as the most important and press were asked to do reviews and leaders below following four overall factors into consid- This included span of control based on the releases as the least. were in some cases confronted with their eration: SCOR model (Buy, Make, Deliver, Plan) E.g. chairman roles in SCM associations, experiences. Based on all these 360-degree and were often correlated to the executive driver positions in SCM related national feedback the net list of executives was 1 Company: Financial performance level of the leader. projects and examinator at universities scored and ranked. 2 Role: Job complexity Secondly, the geographical scope indi- were valued at five points. University 3 Impact: Lighthouse cated each executive’s geographical area of lectures were awarded four points each, to Total score 4 Person: Track record & reputation command with global scope as maximum highlight and recognize those executives The total score for each factor (ranging score. who prioritize and focus on sharing knowl- from 25 to 0 point) was added together to Based on detailed evaluation criteria shown Thirdly, the supply chain complexity was edge, promoting education and attracting arrive at this ranking of the Top 25 Danish in the figure page 2 each factor were ana- evaluated to gain insight into the dynamic promising new talent to the supply chain Supply Chain Executives. lyzed, evaluated, rated and distributed on system of operation within each company. sector. Participation by the Danish supply a scale from max 25 points to 0 points. The Finally, the supply chain maturity was chain executive in keynote presentations winner is the person with total max score. assessed based on the Gartner model. In a or conferences was valued at three points level-one stage or per event. Interviews and own articles in ‘reactive’ supply chain, the focus is solely a weekly, monthly, quarterly or annual 1 based on the business unit. If the supply publication received two points each. Company: Financial performance chain is in a level-five stage of maturity, As a first step, company success was as- technology supports complete orches- sessed based on the latest financial results, tration and value is created for the entire 4 represented by the revenue and EBIT, and network. Person: Track record & reputation ROCE. This entailed extracting the compa- As a final qualifying and most impor- nies’ revenue details and EBIT results from tant step, senior client partner, Katriina their annual reports. 3 Lillelund Schøier from Korn Ferry’s Supply Furthermore, we compared performance Impact: Lighthouse Chain & Operations COE unit assess the in 2019 and 2018 to quantify and evaluate In the third step, we assessed how well the executives track records and personal the improvement in revenue, EBIT and executive succeeded in exposing the supply reputation. Grounded in an evaluation of SUPPLY CHAIN ROCE. chain concept to an audience beyond the the full list of qualified executives, a net EXECUTIVE persons own company. We looked at role list of the topmost qualified executives was model engagements that the leader was developed. The headhunter qualified this 2 involved in outside the company, keynote list further by contacting key people over 2020 Role: Job complexity presentations and university guest lectures, and above the executive to understand the During second step we assessed the press releases and interviews. These criteria performance and track record of the execu- complexity of the leader’s responsibility were then given a weighting value with role tive. Peers inside and outside the company Top 25 Ranking Supply Chain Executives 2020 3 SUPPLY CHAIN LEADERS FORUM And the winner is Torsten Steenholt, EVP and COO at Chr. Hansen A/S science. Torsten is involved in several Mr. Steenholt holds a strong background non-executive board roles in successful from blue-chip supply chain companies, FMCG-companies but also engages him- has consistently demonstrated strong self in delivering presentations, lectures, results over his career and is a strategic interviews, video-casts and tweets about thinker with a holistic end-to-end supply various supply chain and leadership topics. chain view. His market reputation from During the initial COVID-19 crisis he current and former peers, superiors and actively tried to motivate operations people other stakeholders is very strong, and he is across Denmark via the association Danish a persuasive people leader with an ability SUPPLY CHAIN Industry to keep up the good faith and to build high performing, diverse teams. spirit while being safe and delivering good He shows strong supply chain capacity also EXECUTIVE supply chain management. beyond Chr. Hansen – being a true supply The company, Chr. Hansen has under chain role model for all of us. his leadership delivered increasing perfor- Finally, and beyond the formal scoring 2020 mance across all key financial dimensions, criteria, it is worth to mention that the and the supply chain has matured to a level winner is capable of living a balanced The four criteria described previously have aspiring to Gartners level 4. Despite a very work-life with time for his wife and three thoroughly been leveraged, and the result complex global setup with 12 plants and 20 kids, running marathon, reading books discloses a very senior leader, though still distribution centers supplying to a global and playing with gadgets. And once COV- fairly young: 51 years, given his executive market, he and his team have secured an ID-19 is more contained I am sure he will status for more than 3 years. agile, yet resilient and efficient operation again pick up on his eagerness to explore The winner of the SYNCRONIC award across the planet. And this in a such sus- the world and new parts of our beautiful for Best Supply Chain Leader in Denmark tainable manner that it contributed via UN earth. 2020 goes to a person that hold excellent Sustainability Development Goal number track records from leading positions in 12 to place Chr.
Load more

Recommended publications
  • Novo Nordisk Annual Report 2012
    novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012.
    [Show full text]
  • Company Note
    Meet - the Equity Research - management event in managementBoston in event Investment Research Company update 8 February 2017 Novo Nordisk Buy (Unchanged) Pharmaceuticals, Denmark Meet-the-management event in Boston Key data On the day of the FY release, there was much focus on risks due to the changed Price (DKK)* 234 Target price, 12 mth (DKK) † 300 guidance range. The meet-the-management event in Boston on Tuesday had Market cap (DKKm) 606,998 more focus on opportunities. Our impression is that management is talking more Market cap (EURm) 81,652 towards the high end of guidance but that the low end was changed if something Reuters NOVOb.CO unexpected (not very likely) should occur. We keep our DKK300 12M TP and Buy. Bloomberg NOVOB DC No. of shares (m) 2,599.6 Clearer message. Novo has had time to digest how its FY release was received Net debt (current Y/E) (m) -14,353 and its communication has become clearer. The EBIT guidance of -2% to +3% Free float 73.0% Avg. daily vol, 12M (000) 3,376.6 growth in 2017 includes a 4% headwind from Vagifem generics and a tough Norditropin comp. Adjusting for this implies 2-7% growth, which makes it Price performance 400 380 comfortable to deliver 5%-plus after 2017. Cost savings in 2017 from layoffs in 2016 360 340 come to DKK1bn and Novo is set to save a further DKK500m from procurements 320 300 280 in 2017 (and 2018) – savings that have been invested in other parts of Novo. 260 240 220 US.
    [Show full text]
  • PP Hemmingsen
    Lundbeck Foundation EU conference: Giving more to research in Europe Presentation by Steen Hemmingsen, Managing Director, The Lundbeck Foundation - The Danish research funding system - The Danish foundation sector a. Charitable b. Industrial c. Dual purpose (Commercial Foundation Act) - The Lundbeck Foundation - Trust Deed and Governance - Grant policies - Centres of Excellence - Interaction between Foundation controlled pharma industry, university research and biotech cluster March 2006 Lundbeck Foundation TheThe DanishDanish ResearchResearch FundingFunding System*System* Private sector Euro 3,44 bn. 70% 1,78% of GNP Public sector Euro 1,49 bn. 30% 0,79% - - • Council for independent research Euro 124 m. • Council for strategic research Euro 47 m. • National research foundation Euro 27 m. • Technology foundation Euro 26 m. Private foundations**) Euro 134 m. (The Lundbeck Foundation contributes Euro 30 m.) *) Source: The Danish Centre for Studies in Research and Research Policy, some figures relate to 2003. **) Estimate 2005, included in public sector statistics. Lundbeck Foundation THETHE LUNDBECKLUNDBECK FOUNDATIONFOUNDATION • Established in 1954 by Mrs. Grete Lundbeck (no descendants) • Owns 70% of the listed pharmaceutical company H. Lundbeck A/S • An industrial foundation regulated under The Commercial Foundations Act. • Several large Danish companies are controlled by industrial foundations • The Lundbeck Foundation operates independently of its industrial subsidiary/founder family - no company executives on the Board/management - no grants given to company • The Lundbeck Foundation provides grants to research of Euro 30 m. H. Lundbeck A/S has a R&D budget of Euro 250 m. • The Lundbeck Foundation’s asset base is Euro 4 bn. – 65% hereof in donor stock Lundbeck Foundation SeveralSeveral foundationfoundation--ownedowned companiescompanies amongamong thethe largestlargest DanishDanish firmsfirms • A.
    [Show full text]
  • Company Announcement No 27 / 2018 Page 2 of 2
    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 26 March 2018 – On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018. Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018. Since the announcement as of 19 March 2018, the following transactions have been made under the programme: Number of Average Transaction B shares purchase price value, DKK Accumulated, last announcement 4,316,251 1,330,917,830 19 March 2018 145,000 305.81 44,342,263 20 March 2018 145,000 304.49 44,151,273 21 March 2018 145,000 304.84 44,201,837 22 March 2018 147,366 301.24 44,392,350 23 March 2018 150,000 295.35 44,303,071 Accumulated under the programme 5,048,617 1,552,308,624 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 68,110,853 B shares of DKK 0.20, corresponding to 2.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.
    [Show full text]
  • Danish Subsidiaries in Argentina Royal Danish Embassy, Buenos Aires
    DANISH SUBSIDIARIES IN ARGENTINA ROYAL DANISH EMBASSY, BUENOS AIRES Date April 2017 Table of Contents APM Terminals (Terminal 4) ........................................................................................ 3 Arla Foods Ingredients S.A. ........................................................................................... 3 Essentia Argentina S.A. .................................................................................................. 3 Chr. Hansen Argentina S.A.I.C .................................................................................... 4 Coloplast de Argentina .................................................................................................... 4 DAMCO ARGENTINA S.A. ........................................................................................ 4 Danfoss Argentina S.A. ................................................................................................... 5 DSV Air & SEA S.A. ......................................................................................................... 5 ESS-FOOD Argentina ..................................................................................................... 5 Exem Trading S.R.L. (Lego Distr.) ............................................................................ 6 Ferring Argentina S.A. .................................................................................................... 6 Foss S.A. .............................................................................................................................
    [Show full text]
  • Reporter's Handbook
    2O14 RE POR TER’ S HANDBOOK for the biopharmaceutical research industry Member Companies 1 Research Associates 2 U.S. Health-Related Trade and Professional Organizations 3 Government Medical and Health Contacts 4 Voluntary Health Agencies 5 International Pharmaceutical Associations/Health Care Groups 6 Key Facts/About PhRMA 7 Company Products by Category 8 Member Companies 1 Member Companies Abbott Dept 383, AP6D 100 Abbott Park Road Abbott Park, IL 60064-3500 Phone: (847) 937-6100 Fax: (847) 937-1511 Website: www.abbott.com Melissa Brotz, Corporate Public Affairs Office: (847) 935-3456 E-Mail: [email protected] Kelly Morrison, Corporate Public Affairs, Science/Policy Office: (847) 937-3802 E-Mail: [email protected] Scott Stoffel, Corporate Public Affairs, Financial Office: (847) 936-9502 E-Mail: [email protected] Steve Chesterman, Medical Optics Office: (714) 247-8711 E-Mail: [email protected] Jonathon Hamilton, Vascular Devices 3200 Lakeside Drive, Suite 355 Santa Clara, CA 95054 Office: (408) 845-3491 E-Mail: [email protected] AbbVie 1 North Waukegan Road North Chicago, IL 60064 Phone: (847) 932-7900 Website: www.abbvie.com Gulden Mesara, Vice President, Global Commercial and Health Communications Office: (847) 938-2804 E-Mail: [email protected] Angela Sekston, Vice President, Leadership and Employee Communications Office: (847) 937-6636 E-Mail: [email protected] Morry Smulevitz, Head of U.S. Public Affairs Office: (847) 937-2152 E-Mail: [email protected] 1-1
    [Show full text]
  • Social Activity and Investors' Attention on Facebook
    Social activity and Investors’ attention on Facebook - A study exploring the relationship with stock returns Master’s Thesis For the attainment of Master of Science in Economics and Business Administration Applied Economics and Finance at Copenhagen Business School 2015 Authors: Lorenzo Bertolino Stefan Stronciu Supervisors: Ravi Vatrapu, Associate Professor Department of IT management Copenhagen Business School Lisbeth La Cour, Associate Professor Department of Economics Copenhagen Business School Hand-in date: 18th of December 2015 No. of pages: 78 No. of characters (incl. spaces):129’567 Abstract This thesis explores the role of social activity on corporate Facebook fan pages as a proxy for investors’ attention and its relationship with stock returns. Previous researches (Odean, 1999, 2008) proved that non-institutional investors tend to buy stocks that recently grabbed their attention. Starting from this concept we test if the amount of social attention directed toward a certain company is capable of affecting the market behavior of all the actors that trade its stock, that is, if it affects the stock returns of the specific company. Following the aforementioned researches we then narrow our focus on periods of abnormally high social activity and test if this positively impacts the net buying behavior of the market actors and consequently the stock returns. The focus will be on ten of the twenty companies included in the OMXC20 and their respective corporate Facebook fan page. We download from the latter the amounts of Posts, Comments and Likes that have been performed on a daily basis and by using a multiple distributed lag model, in which we also include economic and financial control variables, we try to disclose the existence of any relationship with the stock returns.
    [Show full text]
  • INSULIN-CONTAINING PRODUCTS from NOVO NORDISK Storage, and Savings Information
    Please see the following pages for Tresiba®, ® ® Xultophy 100/3.6, and Fiasp Dosing, 1 INSULIN-CONTAINING PRODUCTS FROM NOVO NORDISK Storage, and Savings Information. BASAL 100 units/mL; total of 200 units/mL; total of 100 units/mL; total of 300 units/pen; 5-pen pack1 600 units/pen; 3-pen pack1 1000 units/vial; 1 vial/pack1 NDC: 0169-2660-15 NDC: 0169-2550-13 NDC: 0169-2662-11 100 units/mL insulin degludec and 3.6 mg/mL liraglutide; total of 300 units insulin degludec and 10.8 mg liraglutide; 5-pen pack2 NDC: 0169-2911-15 BASAL/GLP-1 RA Approved for use in pumps3 Refer to the insulin infusion pump user manual to see if Fiasp® can be used. Use in accordance with the insulin pump’s Instructions for Use. 100 units/mL; total of 300 units; 100 units/mL; total of 100 units/mL; total of PRANDIAL 5-pen pack3 300 units/pen; 5-cartridge pack3 1000 units/vial; 1 vial/pack3 NDC: 0169-3204-15 NDC: 0169-3205-15 NDC: 0169-3201-11 GLP-1 RA=glucagon-like peptide-1 receptor agonist. Tresiba® Indications and Usage Xultophy® 100/3.6 Indications and Xultophy® 100/3.6 Important Safety Fiasp® Indications and Usage Tresiba® (insulin degludec injection) is indicated to Limitations of Use Information Fiasp® (insulin aspart injection) 100 U/mL is a improve glycemic control in patients 1 year of age and Xultophy® 100/3.6 (insulin degludec and liraglutide injection) rapid-acting insulin analog indicated to improve older with diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS 100 units/mL and 3.6 mg/mL is a combination of insulin ® glycemic control in adult and pediatric patients with degludec and liraglutide and is indicated as an adjunct to diet • Liraglutide, one of the components of Xultophy 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid diabetes mellitus.
    [Show full text]
  • Novo Nordisk
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20- F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 333- 82318 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Not applicable The Kingdom of Denmark (Translation of Registrant’s name into English) (Jurisdiction of incorporation or organization Novo Allé DK- 2880 Bagsværd Denmark (Address of principal executive offices) Jesper Brandgaard Executive Vice President and Chief Financial Officer Tel: +45 4444 8888 E- mail: [email protected] Novo Allé, DK- 2880 Bagsværd, Denmark (Name, Telephone, E- mail and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: B shares, nominal value DKK 0.20 each New York Stock Exchange* American Depositary Receipts, New York Stock Exchange each representing one B share * Not for trading, but only in connection with the registration of American Depositary Receipts, pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the Annual Report: A shares, nominal value DKK 0.20 each: 537,436,000 B shares, nominal value DKK 0.20 each: 2,012,564,000 Indicate by check mark if the registrant is a well- known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report 2019 (PDF)
    Novo Nordisk Annual Report 2019 ROSHNI Roshni has type 1 diabetes and lives in India Contents Management review Consolidated statements Introducing Novo Nordisk Consolidated financial statements 01 Letter from the Chair 42 Income statement 02 Letter from the CEO 43 Cash flow statement 04 Novo Nordisk at a glance 44 Balance sheet 06 Performance highlights 45 Equity statement 46 Notes to the consolidated financial statements Our business Consolidated social statement 08 Leading a sustainable business (Supplementary information) 11 Innovative treatments and solutions for unmet needs 14 Pipeline overview 78 Statement of social performance 16 International Operations: Building a sustainable 78 Notes to the consolidated social statement platform for accelerated growth 18 North America Operations: Ready for growth in a challenging business environment Consolidated environmental statement 20 2019 performance and 2020 outlook (Supplementary information) 84 Statement of environmental performance Governance 84 Notes to the consolidated environmental statement 29 Managing risks to protect value 32 Shares and capital structure Additional information 34 Corporate governance 38 Board of Directors 87 Management´s statement and Auditor´s reports 40 Executive management 91 More information 92 Product overview Roshni lives in India, and loves her school. She is 12 years old and wants to become a doctor. Roshni was diagnosed with type 1 diabetes at the age of four. The first few months were tough. It was hard to get the blood sugar levels right. Then she was referred to a hospital and enrolled in Novo Nordisk’s Changing Diabetes in Children programme, which offers free insulin, help on managing diabetes and support for her and her family.
    [Show full text]
  • Danmarks Nationalbank
    STATISTI CS DANMARKS NATIONALBANK 26 JULY 2019 PORTFOLIO INVESTMENTS, JUNE 2019 Foreign investors buy Danish shares in the first half of 2019 Foreign investors have bought listed Danish shares sold some Danish shares, including Danske Bank, for kr. 4.3 billion in the first half of 2019. Foreign in- William Demant and ISS. vestors own a total of kr. 1,345 billion Danish shares corresponding to an ownership of 52 per cent of the Novo Nordisk is foreign investor's favorite share Danish stock market. Foreign investors have owned Foreign investors own entire kr. 458 billion of the more than half of Danish shares since the beginning Danish Novo Nordisk B share. The share thus of 2014. amounts to 34 per cent of their total holdings of Dan- ish shares. Next, foreign investors have the largest It is especially shares in the large Danish companies holdings of shares in DSV, Ørsted and Vestas, which such as Novo Nordisk B, A. P. Møller - Mærsk, Ves- they own respectively own kr. 84, 79 and 78 billion of. tas, Genmab and DSV the foreign investors have The four largest shares thus constitute more than half pur-chased. However, foreign investors have also of foreign investors' portfolio of Danish shares. The Novo Nordisk share is also the most popular Dan- ish share with the Danish investors. They own a total Foreign investors have bought for kr. 4.3 billion of kr. 164 billion thereof. However, the share amounts Danish listed shares in 2019 to only 13 per cent of Danish investors' portfolio of Danish shares, which amounts to kr.
    [Show full text]
  • Creating Shared Value Through Socially Responsible Initiatives in the United States
    The Blueprint for TheChange Blueprint Program for Change Program January 2012 03 January 2012 Creating shared value through socially responsible initiatives in the United States We believe that a healthy economy, environment, and society are fundamental to long-term business growth. This is why we manage our business in accordance with the Triple Bottom Line principle and pursue business solutions that maximize value to business and society. This report details how this principle has contributed to our success in the United States. DOLORES REISNER USADOLORES REISNER USADolores has type 2 diabetes Dolores has type 2 diabetes v creating shared value in the United States v creating shared value in the United States 2 Contents Creating shared value 3 The Blueprint for Change Program The Blueprint for Change Program contents creating shared value If we… We seek to The Triple Bottom Line: Creating shared value 3 address barriers to high-quality care for patients change diabetes A commitment to sustainable and those at risk of type 2 diabetes… and establish our growth have a positive societal impact in the communities presence in a Corporate social responsibility Our approach 4 we call home… holistic way, What is shared value? is not only a moral decision. partner with our stakeholders to help them reach addressing Put quite simply, shared value means what is good Evidence now shows that socially The challenge 6 their goals… patient, societal, for patients, our employees, and our communities responsible activities can help and stakeholder is
    [Show full text]